Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 1
1982 1
1984 2
1985 3
1986 3
1987 7
1988 1
1989 1
1991 2
1992 2
1993 4
1994 4
1995 2
1996 4
1997 5
1998 9
1999 4
2000 3
2001 4
2002 7
2003 5
2004 9
2005 8
2006 11
2007 15
2008 10
2009 11
2010 23
2011 20
2012 24
2013 20
2014 24
2015 31
2016 25
2017 25
2018 38
2019 41
2020 40
2021 39
2022 19
Text availability
Article attribute
Article type
Publication date

Search Results

450 results
Results by year
Filters applied: . Clear all
Page 1
The NAD+/PARP1/SIRT1 Axis in Aging.
Mendelsohn AR, Larrick JW. Mendelsohn AR, et al. Rejuvenation Res. 2017 Jun;20(3):244-247. doi: 10.1089/rej.2017.1980. Rejuvenation Res. 2017. PMID: 28537485
Reading Aloud, Play, and Social-Emotional Development.
Mendelsohn AL, Cates CB, Weisleder A, Berkule Johnson S, Seery AM, Canfield CF, Huberman HS, Dreyer BP. Mendelsohn AL, et al. Pediatrics. 2018 May;141(5):e20173393. doi: 10.1542/peds.2017-3393. Epub 2018 Apr 9. Pediatrics. 2018. PMID: 29632254 Free PMC article. Clinical Trial.
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.
Mease PJ, Chohan S, Fructuoso FJG, Luggen ME, Rahman P, Raychaudhuri SP, Chou RC, Mendelsohn AM, Rozzo SJ, Gottlieb A. Mease PJ, et al. Among authors: mendelsohn am. Ann Rheum Dis. 2021 Sep;80(9):1147-1157. doi: 10.1136/annrheumdis-2020-219014. Epub 2021 May 13. Ann Rheum Dis. 2021. PMID: 33985942 Free PMC article. Clinical Trial.
Interleukin-7 and Immunosenescence.
Nguyen V, Mendelsohn A, Larrick JW. Nguyen V, et al. Among authors: mendelsohn a. J Immunol Res. 2017;2017:4807853. doi: 10.1155/2017/4807853. Epub 2017 Apr 6. J Immunol Res. 2017. PMID: 28484723 Free PMC article. Review.
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
Thaci D, Piaserico S, Warren RB, Gupta AK, Cantrell W, Draelos Z, Foley P, Igarashi A, Langley RG, Asahina A, Young M, Falqués M, Pau-Charles I, Mendelsohn AM, Rozzo SJ, Reich K. Thaci D, et al. Among authors: mendelsohn am. Br J Dermatol. 2021 Aug;185(2):323-334. doi: 10.1111/bjd.19866. Epub 2021 May 4. Br J Dermatol. 2021. PMID: 33544883 Clinical Trial.
450 results